Pien Tze Huang (600436.SH): The first subject has been enrolled in Phase IIa clinical trial PZH2108 in group A.

Zhtng Cijng APP news, The announcement of PianZaiHuang (600436.SH) stated that the company's research and development of chemical drug 1 innovative drug PZH2108 tablets has completed the first subject enrolled in a multicenter, randomized, double-blind, placebo-controlled Phase IIa clinical trial to evaluate the safety, tolerability, preliminary clinical efficacy, pharmacokinetics, and pharmacodynamic characteristics of PZH2108 tablets in cancer patients, marking the formal entry into the Phase IIa clinical trial.